

# Year-end Report 2010

The full year (the Group as a whole)

- Net sales totalled SEK 1,268 million (1,071)
- Profit after tax amounted to SEK 72 million (-9)
- Earnings per share were SEK 10.60 (-1.30)
- At the end of April, the subsidiary NPB won an order from the USA worth SEK 75 million
- All shares in Inmedic AB and its subsidiaries were sold in August
- As of 1 November, all shares in Bladhs Industri AB and its subsidiaries were sold

The full year (continuing operations)

- Net sales totalled SEK 1,049 million (828)
- Profit after tax amounted to SEK 53 million (1)
- Earnings per share were SEK 7.80 (0.25)

The fourth quarter (continuing operations)

- Net sales totalled SEK 295 million (237)
- Profit after tax amounted to SEK 16 million (5)
- Earnings per share were SEK 2.35 (0.85)

The figures referring to continuing operations exclude profit from operating activities as well as profit from the sale of Inmedic and Bladhs Industri. In the specification on page 8, the profit for both continuing and discontinued operations and the Group as a whole are shown.

# CEO's comments on the Group's development during the period

The Group is reporting yet another strong quarter with a continued upturn in sales and healthy profit levels. Volumes have returned to 2008 levels while maintaining good profitability.

The capacity adjustments implemented during 2009 have meant a more flexible way of working and also a more efficient use of the companies' resources. As a result, the adjustment required due to the sudden upturn in the economy seen during the year could take place with the production processes only being exposed to limited interruptions. There are still areas in which improvements can be made and thus good potential for further strong profitability in future.

The current order situation indicates that the positive earnings trend will continue well into the first quarter of 2011.

# Sales

The full year

For continuing operations, net sales amounted to SEK 1,049 million (828), an increase of 27 per cent compared to the previous year. Net sales for discontinued operations were SEK 225 million (250) and for the Group as a whole SEK 1,268 million (1,071).

# The fourth quarter

For continuing operations, net sales amounted to SEK 295 million (237) and for discontinued operations SEK 22 million (64). Net sales for the Group as a whole amounted to SEK 316 million (299).

# Profit

The full year

The operating profit for continuing operations amounted to SEK 83 million (15), corresponding to an operating margin of 8.0 per cent (1.8). Profit before tax was SEK 69 million (2). This result includes non-recurring items totalling SEK 4 million (0) attributable to the disposal of a product range.

Profit before tax for discontinued operations was SEK 7 million (-11) with regard to operating activities and SEK 13 million (0) with regard to the sale of shares in subsidiaries.

For the Group as a whole, profit before tax amounted to SEK 89 million (-9), including non-recurring items totalling SEK 17 million (0).

The fourth quarter

The operating profit for continuing operations amounted to SEK 22 million (10) and profit before tax to SEK 19 million (7). Profit before tax for discontinued operations was SEK 1 million (-1). For the Group as a whole, profit before tax amounted to SEK 20 million (6).

# Share data and key figures

The full year

Earnings per share for continuing operations were SEK 7.80 (0.25). Earnings per share for the Group as a whole were SEK 10.60 (-1.30) and equity per share SEK 65.70 (57.50). The average number of outstanding shares was 6,788,974 during the period. The equity/ assets ratio was 46 per cent (34) at the end of the period. The average number of employees was 873 (851).

# Important events during the year

NPB won a large order from the world's leading manufacturer of metal packaging for food at the end of April. The customer, which is based in the USA, has ordered 13 packaging centres for delivery in 2011. The value of the order amounts to the equivalent of SEK 75 million

All shares in Inmedic AB and its subsidiaries were sold to Hammarplast Medical AB in August. The purchase sum, which was paid in cash, amounted to SEK 21 million and brought a capital gain of SEK 13 million. The sale will henceforth have a minor impact on XANO's profit and financial position. The Inmedic Group has annual sales of approx. SEK 37 million.

As of 1 November, Bladhs Industri AB and its subsidiaries Bladhs Plast Bredaryd AB, Bladhs Plast Gislaved AB, Bladhs Eesti AS and Profilspecialisten AB were sold to Talent Plastics AB. The companies have total annual sales of approx. SEK 240 million, with an operating margin of approx. 5 per cent. 210 employees were affected by this deal. The purchase sum, SEK 46 million, was paid in cash on the day of transfer. The sale had little impact on the profit for the year.

Both Inmedic and Bladhs were part of XANO's business unit Plastic Components.

#### Events after the balance sheet date

There are no individual events of major importance to report after the closing day.

### **Rotational Moulding**

Rotational Moulding manufactures plastic products in the form of components and systems through rotational moulding. Deliverables cover both customer-specific and inhouse developed products in equal measure.

	2010 Full year	2009 Full year
Sales, SEK m	165	151
Operating profit, SEK m	29	6
Operating margin, %	18.0	4.0
The operating profit includes non- recurring items totalling SEK m	4	0

The outcome for the period was very good. The expected seasonal downturn during the fourth quarter did not take place, and sales during the last three months of the year exceeded the levels of the previous year by a healthy margin. For the year as a whole, sales increased despite the fact that one product range was lost due to its sale. A strong recovery within key customer segments, as well as success in new markets, has played a part here.

## **Precision Technology**

Precision Technology covers component and system manufacture through advanced cutting machining of metal and plastic for the production of components with stringent requirements for quality and precision.

	2010 Full year	2009 Full year
Sales, SEK m	339	251
Operating profit/loss, SEK m	19	-10
Operating margin, %	5.5	-4.3

The Precision companies performed well during the fourth quarter thanks to a strong upturn in sales in combination with positive effects gained from restructuring work already completed. For the year as a whole, a remarkable recovery was achieved following on from the previous year's negative outcome. Further-

more, there is additional potential for improvement through continued organisational changes and more efficient use of capacity.

#### **Industrial Solutions**

Industrial Solutions supplies customer-specific automation solutions for the food and medical technology industries, in addition to packaging machines for beverage and other food packaging. Manufacturing also covers inhouse developed conveyor systems for food products and handling equipment for a variety of applications.

	2010 Full year	2009 Full year
Sales, SEK m	495	381
Operating profit, SEK m	36	23
Operating margin, %	7.3	6.0

Fredriksons' Swedish unit ended the year with continued good sales, but somewhat worse outcome as a result of a number of redundancies and extra costs in conjunction with flow changes in the production premises. The very positive trend continued at the Chinese unit during the fourth quarter and the planned move was completed in a very satisfactory manner. 2010 was a generally good year for Fredriksons with continuous sales growth and good profitability.

NPB reported a small but positive result during the fourth quarter. High production development costs and fewer installations due to a freeze on investments by several major customers did, however, mean that the result for the year was negative. The large order placed in the USA last spring is in production and will have an impact on profits during 2011.

# Plastic Components

Plastic Components offers development and manufacturing services within injection moulding and extrusion of plastic. Deliverables cover both customer-specific components and systems, as well as in-house developed products. During the second half of 2010, Inmedic and Bladhs, plus their subsidiaries, were sold. The discontinued operations had made up the majority of the business unit Plastic Components, which is why its activities were discontinued at the turn of the year. Ackurat, which was the only remaining company in the unit, will now be part of the business unit Industrial Solutions and report within this segment from 1 January 2011.

	2010 Full year	2009 Full year
Sales, SEK m	274	292
Operating profit, SEK m	36	3
Operating margin, %	13.2	1.2
The operating profit includes non- recurring items totalling SEK m	13	0

As for all of 2010, Ackurat reported stable sales and very good profitability during the fourth quarter. In addition to the general economic situation, presence on new markets and an even more expanded product range have also helped the continued success.

#### Investments

During the year, the Group's net investments in fixed assets amounted to SEK -80 million (29), of which SEK -109 million related to corporate transactions, SEK 4 million to real estate and SEK 25 million to machinery and equipment.

Net investments during the fourth quarter were SEK -90 million (7), of which SEK -107 million related to corporate transactions, SEK 3 million to real estate and SEK 14 million to machinery and equipment.

#### Cash flow and liquidity

Cash flow after investments was SEK 156 million (106) during the year. It is primarily the profit from an increase in volume that has contributed to the year's cash flow, while the previous year's cash flow was mainly generated by less capital being tied up.

The Group's liquid assets, including lines of credit granted but not utilised, totalled SEK 484 million (322) on the balance sheet date.

# Risks and uncertainty factors

The Group's major risk and uncertainty factors include operational risks associated with customers and suppliers and other external factors such as price risks for input goods. In addition, there are financial risks as a result of changes in exchange rates and interest rate levels.

A statement on the Group's main financial and operational risks can be found on pages 55 and 56 of the annual report for 2009. No additional significant risks are deemed to have arisen.

# Accounting principles

As with the accounts for 2009, the consolidated financial statements for 2010 were prepared in accordance with the International Financial Reporting Standards (IFRS), as adopted by the EU, the Swedish Annual Accounts Act and the recommendations and statements of the Swedish Financial Reporting Board. This interim report has been prepared in accordance with IAS 34. The Group applies the same accounting policies as described in the annual report for 2009 with the following exceptions as a result of new or revised standards, interpretations and improvements, which are applied as of 1 January 2010. Only those changes that have had or could have an effect on the Group are covered by the report.

IFRS 3R Business Combinations and IAS 27R Consolidated and Separate Financial Statements

The new rules mean, amongst other things, that transaction fees on business combinations must be reported as a cost and also that conditional purchase sums must be set at the fair value at the time of acquisition and that the effects of revaluations of these purchase sums must be reported in the profit for the year. The new rules will have an impact on the reporting of future acquisitions.

IFRIC 16 Hedges of a Net Investment in a Foreign Operation

The interpretation may have an impact on future hedge reporting.

#### RFR 2 Accounting for Legal Entities

This recommendation means, amongst other things, that IAS 1 Presentation of Financial Statements is also to be applied to the Parent Company. This application has not had any effect on the company's financial position.

#### Other

In addition to this, the Parent Company has changed the accounting policy for Group currency accounts, which means that the balance sheet total has risen.

Board member

#### Discontinued operations

The subsidiary Inmedic AB was sold in August and the sale of Bladhs Industri AB was completed in November.

Profit from the sold units' operating activities and the sales is recognised in accordance with IFRS 5 as discontinued operations. All comparison periods have therefore been changed.

#### Proposed dividend

The Board of Directors proposes to the Annual General Meeting a dividend of SEK 2.00 (1.50) per share, totalling SEK 14 million (10) based on the number of outstanding shares at year-end

In addition to this, the Board of Directors proposes an additional dividend of SEK 1.50 (0) per share, totalling SEK 10 million (0).

#### Repurchase of own shares

The Board of Directors proposes that the Annual General Meeting renew the Board's authorisation to approve the repurchase of the company's own shares. Such a mandate would empower the Board, during the period until the next Annual General Meeting, to make decisions regarding the repurchase of the company's shares.

Any such repurchase could be effected both via the stock market and by offers to the share-

holders. It is proposed that the mandate to the Board should also include scope for assigning repurchased shares within the constraints of relevant legislation.

#### Nomination committee

A nomination committee was appointed at the 2010 Annual General Meeting consisting of Ulf Hedlundh (chairman), Johan Rapp and Petter Johansson. The task of the committee prior to the 2011 AGM is to nominate a chairman of the board and other board members, a chairman for the AGM and fees for the board, committees and auditors.

#### **Annual General Meeting**

The Annual General Meeting will be held on Friday 6 May at 3.00 p.m. at XANO's premises at Industrigatan 14 B in Jönköping.

The annual report for 2010 will be available in week 14, as a printed version at the head office and in digital format on the website www.xano.se. The annual report will be distributed via normal post to all shareholders along with information concerning the AGM.

#### Next report date

CEO

The interim report for the period 1 January to 31 March 2011 will be presented on Friday 6 May 2011.

The undersigned declare that the year-end report provides an accurate summary of the Parent Company's and the Group's activities, position and results. It also describes significant risks and uncertainty factors faced by the Parent Company and the companies that form the Group.

Jönköping, 10 February 2011

Thord Johansson Johan Rapp Eva Nilsson Fredrik Rapp
Chairman of the Board Vice Chairman of the Board Board member

Stig-Olof Simonsson Christer Dahlström Sune Lantz

This report has not been reviewed by the company's auditors.

Board member

Consolidated statement of comprehensive income	2010	2009	2010	2009
(SEK million)	3 mths Oct-Dec	3 mths Oct-Dec	12 mths Jan-Dec	12 mths Jan-Dec
Net sales	295	237	1,049	828
Cost of goods sold	-245	-195	-857	-701
Gross profit	50	42	192	127
Other operating income 1)	6	0	16	5
Selling expenses	-21	-20	-78	-73
Administrative expenses	-11	-11	-42	-41
Other operating expenses	-2	-1	-5	-3
Operating profit	22	10	83	15
Financial items	-3	-3	-14	-13
Profit before tax	19	7	69	2
Tax	-3	-2	-16	-1
Profit from continuing operations for the period	16	5	53	1
Profit/loss from discontinued operations <sup>2)</sup>	1	-1	19	-10
Net profit/loss for the period	17	4	72	-9
Other comprehensive income				
Change in hedging reserve including tax 3)	1	0	2	0
Exchange rate differences 4)	0	1	-8	-5
Comprehensive income for the period	18	5	66	-14
For the Group as a whole, depreciation constitutes	14	17	63	71

Tax totals 20% (-2) for the full year. Tax-exempt capital gain has contributed to the lower tax expense in 2010. Variations in tax rates at non-Swedish subsidiaries contributed to the previous year's reduced tax rate.

<sup>&</sup>lt;sup>4)</sup> Exchange rate differences refer to the effects of changes in exchange rates when net investments in non-Swedish subsidiaries are translated to SEK. The amount is reported net of hedging contracts.

Share data	2010	2009	2010	2009
	3 mths	3 mths	12 mths	12 mths
	Oct-Dec	Oct-Dec	Jan-Dec	Jan-Dec
Average number of outstanding shares, thousands Average number of outstanding shares after dilution, thousands Average number of shares in own custody, thousands	6,789	6,789	6,789	6,789
	7,009	7,009	7,009	7,009
	140	140	140	140
Basic earnings per share for continuing operations, SEK <sup>1)</sup> Diluted earnings per share for continuing operations, SEK <sup>1, 2)</sup> Basic earnings per share for the Group as a whole, SEK <sup>1)</sup> Diluted earnings per share for the Group as a whole, SEK <sup>1, 2)</sup> Cash flow from operating activities per share for the Group as a whole, SEK	2.35	0.85	7.80	0.25
	2.35	0.85	7.70	0.25
	2.50	0.65	10.60	-1.30
	2.45	0.65	10.40	-1.30
Total number of shares on balance sheet date, thousands Number of shares in own custody on balance sheet date, thousands Equity per share on balance sheet date, SEK Share price on balance sheet date, SEK			6,929 140 65.70 83.00	6,929 140 57.50 56.00

After deduction for the company's own holding, 140,000 Class B shares, the number of outstanding shares is 6,788,974.

In July 2008, 220,000 convertibles, corresponding to 220,000 Class B shares in the event of full conversion, were issued. The convertibles accrue interest corresponding to STIBOR 12M plus 1.5% and fall due for payment on 30 June 2012.

<sup>&</sup>lt;sup>1)</sup> Other operating income for the full year includes non-recurring items amounting to SEK 4 million (0), attributable to the disposal of a product range.

<sup>&</sup>lt;sup>2)</sup> Profit/loss from discontinued operations refers to Inmedic AB and Bladhs Industri AB. This result includes non-recurring items totalling SEK 13 million (0), attributable to capital gain/loss from the sale of shares in subsidiaries. See specification on page 8.

<sup>&</sup>lt;sup>3)</sup> Refers to the effective component of the change in value of derivative instruments used for hedge reporting.

<sup>1)</sup> Based on net profit/loss for the period.

<sup>&</sup>lt;sup>2)</sup> No dilution effect is taken into account when diluted earnings per share are higher than basic earnings per share.

Consolidated statement of financial position (SEK million)	2010 31 Dec	<b>2009</b> 31 Dec
ASSETS		
Goodwill	178	210
Other intangible fixed assets	6	9
Tangible fixed assets	410	540
Financial fixed assets	0	0
Total fixed assets	594	759
Inventories	186	206
Current receivables	185	182
Cash and bank balances	11	11
Total current assets	382	399
TOTAL ASSETS	976	1,158
EQUITY AND LIABILITIES		
Equity	446	390
Non-current liabilities	216	329
Current liabilities	314	439
TOTAL EQUITY AND LIABILITIES	976	1,158
Interest-bearing liabilities constitute	282	540
Deferred tax liabilities constitute	36	45

Divested assets and liabilities relating to Inmedic AB amounted to SEK 12 million and SEK 5 million respectively.

Divested assets and liabilities relating to Bladhs Industri AB amounted to SEK 188 million and SEK 146 million respectively, of which interest-bearing liabilities constituted SEK 102 million.

Statement of changes in equity (SEK million)	<b>2010</b> 31 Dec	2009 31 Dec
Opening balance	390	414
Comprehensive income for the period	66	-14
Dividend paid	-10	-10
Closing balance	446	390

Cash flow statement	2010	2009
(SEK million)	12 mths Jan-Dec	12 mths Jan-Dec
Operating profit	105	7
Adjustments for non-cash items etc.	28	62
Change in working capital	-7	55
Cash flow from operating activities	126	124
Investments	30	-18
Cash flow after investments	156	106
Financing	-156	-113
Change in liquid assets	0	-7

The cash flow statement refers to the Group as a whole, including discontinued operations.

Of the total cash flow, discontinued operations' cash flow from operating activities totalled SEK 19 million (37), cash flow from investing activities SEK 53 million (-6) and cash flow from financing activities SEK -72 million (-31).

Key ratios	2010 12 mths Jan-Dec	2009 12 mths Jan-Dec
Operating margin for continuing operations, %	8.0	1.8
Operating margin for the Group as a whole, %	8.3	0.6
Profit margin for continuing operations, %	6.6	0.3
Profit margin for the Group as a whole, %	7.1	-0.8
Return on equity, % 1)	17.4	-2.2
Return on capital employed, % 1)	12.4	1.7
Return on total capital, % 1)	9.6	1.4
Interest coverage ratio, multiple 1)	5.8	0.7
Equity, SEK m	446	390
Equity/assets ratio, %	46	34
Proportion of risk-bearing capital, %	49	38
Net investments for continuing operations, SEK m	25	25
Net investments for the Group as a whole, SEK m	-80	29
Average number of employees for continuing operations	677	606
Average number of employees for the Group as a whole	873	851

For definitions, see page 56 of the 2009 annual report.

<sup>1)</sup> Refers to the whole Group, including discontinued operations.

Quarterly summary	2010	2009	2010	2009	2010	2009	2010	2009
	Q4	Q4	Q3	Q3	Q2	Q2	Q1	Q1
Net sales for continuing operations, SEK m	295	237	228	182	293	202	233	207
Gross profit for continuing operations, SEK m	50	42	43	29	57	25	42	31
Operating profit/loss for continuing operations, SEK m	22	10	19	6	26	-3	16	2
Profit/loss before tax for continuing operations, SEK m	19	7	15	3	23	-8	12	0
Net profit/loss for the period for continuing operations, SEK m	16	5	11	3	17	-7	9	0
Net profit/loss for the period for the Group as a whole, SEK m	17	4	24	3	21	-9	10	-7
Comprehensive income for the period, SEK m	18	5	21	-5	21	-9	6	-5
Operating margin for continuing operations, %	7.5	4.4	8.6	2.7	9.0	-1.4	6.6	1.1
Equity/assets ratio, %	46	34	38	33	34	32	33	32
Earnings per share for continuing operations, SEK	2.35	0.85	1.65	0.35	2.50	-1.00	1.30	0.05
Earnings per share for the Group as a whole, SEK	2.50	0.65	3.50	0.35	3.15	-1.30	1.45	-1.00
Cash flow from operating activities per share, SEK <sup>1)</sup>	5.40	4.35	6.55	2.30	6.10	9.50	0.45	2.20

<sup>&</sup>lt;sup>1)</sup> Refers to the whole Group, including discontinued operations.

# Net sales and profit/loss by segment

			2010			2009			
(SEK million)	External	Net sales	Total	Profit/loss before tax 1)	Extern	Net sale	rs Total	Profit/loss before tax 1)	
Rotational Moulding	165	0	165	25 <sup>2)</sup>	15	1 0	151	6	
Plastic Components	272	2	274	32 3)	28	9 3	292	-5	
Precision Technology	336	3	339	13	25	) 1	251	-16	
Industrial Solutions	495	0	495	32	38	1 0	381	19	
Eliminations	_	-5	-5	_		4	-4	-	
Undistributed items 1)	-	-	-	-13			-	-13	
Group total	1,268	0	1,268	89	1,07	1 0	1,071	-9	

The segment reporting refers to the whole Group, including discontinued operations. IFRS 8 Operating Segments, which supersedes IAS 14, is applied as of 1 January 2009. This standard requires information to be provided from the managements perspective, which means that the reporting corresponds with the way in which the information is presented internally. The Group reports on the following segments: Rotational Moulding, Plastic Components, Precision Technology and Industrial Solutions. The operations within each segment are described on pages 2 and 3. No changes have been made to the basis for subdivision into segments in relation to the annual report for 2009. The segments are reported in accordance with the same reporting principles as the Group. Market conditions are applied to transactions between the segments.

In 2010, all segments have boosted their total operating assets, such as inventories and trade receivables, as a result of an increase in the order book. A lower investment level and currency fluctuations have contributed to tangible fixed assets being reduced in all segments. The sale of Inmedic and Bladhs Industri led to total assets being reduced by SEK 200 million.

<sup>&</sup>lt;sup>1)</sup> The profit/loss figure refers to the profit/loss before the distribution of group-wide costs and tax in accordance with internal reporting. Undistributed items are mainly costs for the Parent Company.

<sup>&</sup>lt;sup>2)</sup> This figure includes non-recurring items totalling SEK 4 million attributable to the disposal of a product range.

<sup>&</sup>lt;sup>3)</sup> Includes profit from Inmedic up to and including its sale in August 2010 and Bladhs Industri up to and including its sale in November 2010. This figure includes non-recurring items totalling SEK 13 million attributable to the sale of shares in Inmedic AB and Bladhs Industri AB.

Income statement, Parent Company		2009	
(SEK million)	12 mths Jan-Dec	12 mths Jan-Dec	
Net sales	9.8	11.0	
Selling and administrative expenses	-15.0	-14.9	
Other operating income/expenses	2.1	0.9	
Operating profit/loss	-3.1	-3.0	
Financial items	2.5	1.3	
Profit/loss after financial items	-0.6	-1.7	
Appropriations	-8.6	2.9	
Tax	2.3	-0.7	
Net profit/loss for the period	-6.9	0.5	

Income tax totals 25% (54).

Share data, Parent Company	2010 12 mths Jan-Dec	2009 12 mths Jan-Dec
Average number of outstanding shares, thousands Average number of outstanding shares after dilution, thousands Average number of shares in own custody, thousands	6,789 7,009 140	6,789 7,009 140
Basic earnings per share, SEK Diluted earnings per share, SEK <sup>1)</sup>	-1.01 -1.01	0.08 0.08

<sup>&</sup>lt;sup>1)</sup> No dilution effect is taken into account when diluted earnings per share are higher than basic earnings per share.

Balance sheet, Parent Company (SEK million)	2010 31 Dec	2009 31 Dec
ASSETS		
Fixed assets	71.3	71.5
Current assets	524.6	508.6
EQUITY AND LIABILITIES		
Equity	266.2	245.9
Untaxed reserves	18.8	10.2
Non-current liabilities	41.6	43.5
Current liabilities	269.3	280.5
BALANCE SHEET TOTAL	595.9	580.1

The Parent Company's net investments in fixed assets during the period totalled SEK 0.1 million (-0.1).

The Parent Company's liquid assets, including external lines of credit granted but not utilised, totalled SEK 391 million (213) on the balance sheet date, an increase of SEK 178 million during the year.

Dividends totalling SEK 10 million (10) were paid.

The Parent Company has changed the accounting policy for Group currency accounts. The subsidiaries' claims on and debts to internal lines of credit are now recognised as liabilities to and receivables from Group companies. The Group's total debt to the bank is recognised as liability in the Parent Company. As a consequence of this change, the balance sheet total has risen. The comparison period has been recalculated.

Income statements	Continuing operations		Discontinued operations 1)		Profit from disposals 2)		Internal sales		Total	
(SEK million)	2010	2009	2010	2009	2010	2009	2010	2009	2010	2009
Net sales	1,049	828	225	250	_	_	-6	-7	1,268	1,071
Cost of goods sold	-857	-701	-191	-226	_	-	4	4	-1,044	-923
Gross profit/loss	192	127	34	24	0	0	-2	-3	224	148
Other operating income	16	5	3	3	13	_	_	-	32	8
Selling expenses	-78	-73	-16	-21	_	-	-	-	-94	-94
Administrative expenses	-42	-41	-7	-9	_	-	-	-	-49	-50
Other operating expenses	-5	-3	-3	-2	-	-	-	-	-8	-5
Operating profit/loss	83	15	11	-5	13	0	-2	-3	105	7
Financial items	-14	-13	-2	-3	-	-	_	-	-16	-16
Profit/loss after financial items	69	2	9	-8	13	0	-2	-3	89	-9
Group-wide costs	-	-	-2	-3	-	-	2	3	-	_
Profit/loss before tax	69	2	7	-11	13	0	0	0	89	-9
Tax	-16	-1	-1	1	_	-	_	-	-17	0
Net profit/loss for the period	53	1	6	-10	13	0	0	0	72	-9
Basic earnings per share, SEK <sup>3)</sup>	7.80	0.25	0.95	-1.55	1.85	_	_	_	10.60	-1.30
Diluted earnings per share, SEK 3, 4)	7.70	0.25	0.90	-1.55	1.80	_	_	_	10.40	-1.30

<sup>&</sup>lt;sup>1)</sup> Discontinued operations refer to Inmedic AB and Bladhs Industri AB. The businesses were sold in August and November 2010 respectively and were reclassified as discontinued operations during the year. All comparison periods have therefore been changed. Profit after tax from operating activities amounts to SEK 554 thousand (1,821) for Inmedic and SEK 5,915 thousand (-12,285) for Bladhs Industri.



<sup>&</sup>lt;sup>2)</sup> Profit from disposals refers to the capital gain made on selling the shares in Inmedic AB and Bladhs Industri AB.

<sup>&</sup>lt;sup>3)</sup> Based on net profit/loss for the period.

<sup>&</sup>lt;sup>4)</sup> No dilution effect is taken into account when diluted earnings per share are higher than basic earnings per share.